Amsterdam Molecular Therapeutics NV (AMT) said that its chief executive, Ronald HW Lorijn, has resigned for personal reasons and will be replaced on an interim basis by the gene therapy company’s chief scientific officer, Sander van Deventer.
Prof. van Deventer said “I look forward to guiding AMT at this important stage with the clinical trial of Glybera (a phase 3 product for treating genetic lipoprotein lipase deficiency) and the filing of the marketing authorisation dossier for this product.”
The company said its financial guidance remains unchanged.
Copyright 2009 Evernow Publishing Ltd